|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 274.94 USD | -3.17% |
|
-0.42% | +7.64% |
| Capitalization | 34.15B 29.44B 27.41B 25.52B 47.51B 3,099B 51.11B 315B 124B 1,478B 128B 125B 5,397B | P/E ratio 2025 * |
22.7x | P/E ratio 2026 * | 24x |
|---|---|---|---|---|---|
| Enterprise value | 41.94B 36.16B 33.66B 31.34B 58.35B 3,806B 62.78B 387B 153B 1,815B 157B 154B 6,629B | EV / Sales 2025 * |
0.32x | EV / Sales 2026 * | 0.29x |
| Free-Float |
60.46% | Yield 2025 * |
1.29% | Yield 2026 * | 1.4% |
Last Transcript: Humana Inc.
| 1 day | -3.13% | ||
| 1 week | -0.42% | ||
| Current month | +7.64% | ||
| 1 month | +6.79% | ||
| 3 months | +3.15% | ||
| 6 months | +21.69% | ||
| Current year | +7.64% |
| 1 week | 269.21 |  | 285.6 |
| 1 month | 254.38 | | 285.6 |
| Current year | 256.04 | | 285.6 |
| 1 year | 206.87 | | 315.35 |
| 3 years | 206.87 | | 541.21 |
| 5 years | 206.87 | | 571.3 |
| 10 years | 150 | | 571.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Rechtin
CEO | Chief Executive Officer | 55 | 30/06/2024 |
Celeste Brown
DFI | Director of Finance/CFO | 49 | 10/01/2025 |
Japan Mehta
CTO | Chief Tech/Sci/R&D Officer | 45 | 31/01/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kurt Hilzinger
CHM | Chairman | 65 | 31/12/2013 |
Frank D'Amelio
BRD | Director/Board Member | 68 | 31/08/2003 |
Karen Katz
BRD | Director/Board Member | 69 | 22/09/2019 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | 0.00% | 2.3% | 5 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -3.17% | -0.42% | -0.04% | -43.79% | 34.15B | |
| -1.95% | -3.29% | -34.85% | -31.42% | 307B | |
| -1.50% | +0.82% | -2.43% | -21.85% | 84.88B | |
| -1.96% | -2.36% | -3.06% | -13.54% | 74.24B | |
| -2.12% | -0.68% | -26.36% | -39.67% | 23.23B | |
| -0.95% | +5.60% | -32.18% | -35.97% | 9.96B | |
| +0.87% | +9.14% | +55.88% | +77.05% | 4.5B | |
| +1.23% | -8.87% | +19.28% | -27.10% | 2.1B | |
| Average | -1.19% | +0.28% | -2.97% | -17.04% | 67.51B | |
| Weighted average by Cap. | -1.90% | -0.98% | -21.80% | -27.76% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 129B 111B 104B 96.55B 180B 11,725B 193B 1,193B 470B 5,593B 485B 475B 20,422B | 145B 125B 117B 109B 202B 13,180B 217B 1,341B 529B 6,287B 545B 534B 22,957B |
| Net income | 1.51B 1.3B 1.21B 1.13B 2.1B 137B 2.26B 13.93B 5.49B 65.3B 5.66B 5.54B 238B | 1.45B 1.25B 1.16B 1.08B 2.02B 131B 2.17B 13.38B 5.27B 62.71B 5.43B 5.32B 229B |
| Net Debt | 7.79B 6.72B 6.25B 5.82B 10.84B 707B 11.66B 71.94B 28.37B 337B 29.22B 28.62B 1,231B | 7.78B 6.71B 6.25B 5.81B 10.83B 706B 11.65B 71.84B 28.33B 337B 29.18B 28.58B 1,230B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 275.60 $ | -2.94% | 341,731 |
| 15/01/26 | 283.95 $ | +3.58% | 976,925 |
| 14/01/26 | 274.14 $ | +0.07% | 941,603 |
| 13/01/26 | 273.96 $ | -0.95% | 441,603 |
| 12/01/26 | 276.59 $ | -0.09% | 719,029 |
Delayed Quote Nyse, January 16, 2026 at 07:25 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HUM Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition